us

Elite Pharmaceuticals ELTP Stock

$0.28   -1.455810%
Add to favorites
Market Cap
$306.23M
LOW - HIGH [24H]
$0.28 - $0.29
VOLUME [24H]
$36.36K
P/E Ratio
5.68
Earnings per share
$0.05
ISIN
US28659T2006
Price   Prediction

Elite Pharmaceuticals Price Chart

Sorry, that's all we've gotfor now...

Elite Pharmaceuticals ELTP Financial and Trading Overview

Elite Pharmaceuticals stock price 0.28 USD
Previous Close 0.3 USD
Open 0.3 USD
Bid 0.29 USD x 250000
Ask 0.29 USD x 250000
Day's Range 0.29 - 0.3 USD
52 Week Range 0.27 - 0.74 USD
Volume 337.72K USD
Avg. Volume 698.04K USD
Market Cap 312.37M USD
Beta (5Y Monthly) 0.398
PE Ratio (TTM) 5.7999997
EPS (TTM) 0.05 USD
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est N/A

ELTP Valuation Measures

Enterprise Value 278.03M USD
Trailing P/E 5.7999997
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm) 2.215162
Price/Book (mrq) 2.9896905
Enterprise Value/Revenue 1.972
Enterprise Value/EBITDA 7.452

Trading Information

Elite Pharmaceuticals Stock Price History

Beta (5Y Monthly) 0.398
52-Week Change -47.27%
S&P500 52-Week Change 18.35%
52 Week High 0.74 USD
52 Week Low 0.27 USD
50-Day Moving Average 0.36 USD
200-Day Moving Average 0.41 USD

ELTP Share Statistics

Avg. Volume (3 month) 698.04K USD
Avg. Daily Volume (10-Days) 1.33M USD
Shares Outstanding 1.08B
Float 836.08M
Short Ratio 0.87
% Held by Insiders 22.37%
% Held by Institutions 0%
Shares Short 1.61M
Short % of Float N/A
Short % of Shares Outstanding 2.16%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends March 31, 2026
Most Recent Quarter (mrq) June 30, 2026
Next Fiscal Year End March 31, 2027

Profitability

Profit Margin 40.18%
Operating Margin (ttm) 23.27%
Gross Margin 43.47%
EBITDA Margin 26.45%

Management Effectiveness

Return on Assets (ttm) 17.82%
Return on Equity (ttm) 74.31%

Income Statement

Revenue (ttm) 141.01M USD
Revenue Per Share (ttm) 0.13 USD
Quarterly Revenue Growth (yoy) -19.50%
Gross Profit (ttm) 61.31M USD
EBITDA 37.31M USD
Net Income Avi to Common (ttm) 56.67M USD
Diluted EPS (ttm) 0.05
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 38.94M USD
Total Cash Per Share (mrq) 0.04 USD
Total Debt (mrq) 5.57M USD
Total Debt/Equity (mrq) 5.32 USD
Current Ratio (mrq) 3.761
Book Value Per Share (mrq) 0.097

Cash Flow Statement

Operating Cash Flow (ttm) 19.04M USD
Levered Free Cash Flow (ttm) 23M USD

Profile of Elite Pharmaceuticals

Country United States
State NJ
City Northvale
Address 165 Ludlow Avenue
ZIP 07647
Phone 201 750 2646
Website https://www.elitepharma.com
Industry Drug Manufacturers - Specialty & Generic
Sector(s) Healthcare
Full Time Employees 65

Elite Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development, manufacture, and sale of oral, controlled-release products, and generic pharmaceuticals. It owns, licenses, manufactures, and sales of generic, oral dose pharmaceuticals products, such as Phentermine HCl 37.5mg tablets, and 15mg and 30mg capsules to treat bariatrics under Adipex-P brand; Phendimetrazine Tartrate 35mg tablets for bariatrics under the Bontril brand; Naltrexone HCl 50mg tablets for the treatment of pains under the Revia brand; and Isradipine 2.5mg and 5mg capsules for cardiovascular diseases. It also provides Trimipramine Maleate Immediate Release antidepressant capsules under the Surmontil brand; Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Immediate Release tablets under the Adderall brand; Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate Extended Release capsules under the Adderall XR brand for central nervous system diseases; Dantrolene Sodium capsules for muscle relaxant under the Dantrium brand; Methotrexate Sodium 2.5mg tablets for the treatment of Antimetabolite under the Otrexup PF brand; Loxapine Succinate capsules for treating antipsychotic under the Loxapine brand; Acetaminophen and Codeine Phosphate for the management of mild to moderate pain; Acetaminophen and Hydrocodone Bitartrate capsules for the treatment of pain under the Norco brand; Lisdexamfetamine Dimesylate to treat ADHD under the Vyvanse brand; Oxycodone Hydrochloride and Acetaminophen tablets to treat pain under the Percocet brand name; and Methadone Hydrochloride tablets for the treatment of pain under the Dolophine brand. In addition, it manufactures controlled-release products on a contract basis for third parties in the areas of allergy, bariatric, attention deficit, and infection. The company was incorporated in 1997 and is headquartered in Northvale, New Jersey.

Q&A For Elite Pharmaceuticals Stock

What is a current ELTP stock price?

Elite Pharmaceuticals ELTP stock price today per share is 0.28 USD.

How to purchase Elite Pharmaceuticals stock?

You can buy ELTP shares on the OTC Markets OTCQB exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Elite Pharmaceuticals?

The stock symbol or ticker of Elite Pharmaceuticals is ELTP.

Which industry does the Elite Pharmaceuticals company belong to?

The Elite Pharmaceuticals industry is Drug Manufacturers - Specialty & Generic.

How many shares does Elite Pharmaceuticals have in circulation?

The max supply of Elite Pharmaceuticals shares is 1.08B.

What is Elite Pharmaceuticals Price to Earnings Ratio (PE Ratio)?

Elite Pharmaceuticals PE Ratio is 5.68600000 now.

What was Elite Pharmaceuticals earnings per share over the trailing 12 months (TTM)?

Elite Pharmaceuticals EPS is 0.05 USD over the trailing 12 months.

Which sector does the Elite Pharmaceuticals company belong to?

The Elite Pharmaceuticals sector is Healthcare.

$2.67T
Total marketcap
$120.83B
Total volume
BTC 59.18%     ETH 11.13%
Dominance
Select currency